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While the phlogistic activities of IgM or IgG immune complexes (ICs) have been well 
established as complement-activating agents and seem likely to play important roles 
in humans with vasculitis, certain types of glomerulonephritis as well as in a variety 
of autoimmune diseases, the predominant clinical strategies have involved the use of 
immunosuppressive or anti-inflammatory drugs. Over the past decade, new insights 
into molecular events developing during IC models in rodents have identified new phlo-
gistic products that may be candidates for therapeutic blockade. Extracellular histones, 
located in the web-like structures of neutrophil extracellular traps, are released from 
complement-activated polymorphonuclear neutrophils (PMNs) downstream of IC depo-
sition. Extracellular histones appear to be a new class of highly tissue-damaging prod-
ucts derived from complement-activated PMNs. Histones have also been discovered 
in cell-free broncho-alveolar lavage fluids from humans with acute respiratory distress 
syndrome (ARDS). Recent studies emphasize that in the setting of ARDS-like reactions 
in rodents, extracellular histones are released and are exceedingly proinflammatory, 
tissue damaging, and prothrombotic. Such studies suggest that in humans with ARDS, 
extracellular histones may represent therapeutic targets for blockade.
Keywords: extracellular histones, neutrophil extracellular traps, complement, C5a, C5aR1, C5aR2, acute 
respiratory distress syndrome
inTRODUCTiOn
It has been known for at least 50 years that formation of immune complexes (ICs) (involving IgM 
or IgG) results in vascular and renal damage that is complement dependent (1–3). In humans, 
the most common conditions associated with ICs are autoimmune diseases, such as rheumatoid 
arthritis and systemic lupus erythematosus (SLE), and certain types of glomerulonephritis (4–9). 
Viral hepatitis C and HIV infections can result in mixed cryoglobulinemia and vasculitis secondary 
to IC formation (10, 11). In addition, lung diseases, such as acute respiratory distress syndrome 
(ARDS) and acute lung injury (ALI), are reported to be associated with IC deposition (3, 12). ICs 
are defined as antigen–antibody complexes formed by ligation of IgG or IgM to soluble antigen, 
triggering complement activation mainly via the classical pathway. ICs bind to activating and/or 
inhibitory Fcγ receptors (FcRs) to facilitate phagocytosis and to modulate immune cell functions 
(13–15). ICs activate the complement system as an integral arm of innate immunity, which results 
in the formation of the C5b-9 membrane attack complex and generation of anaphylatoxins (C3a 
and C5a) (16). Over the past several years, important new information has been obtained that 
FiGURe 1 | Histopathology of mouse lungs in normal lungs and lungs after ALi following airway deposition of igGiC in C57BL/6J mice. (A) Histological 
features of normal mouse lung. (B) Positive control (acutely injured lung induced by airway deposition of IgGIC) 6 h after induction of ALI showing lung infiltration of 
PMNs, intra-alveolar hemorrhage, and hyaline membranes (arrow). Images modified from Bosmann et al. (18). Both frames are from paraffin-embedded sections 
stained with hematoxylin and eosin (×40 view; insets: ×100 view).
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expands our knowledge of the molecular events that are linked 
to IC-induced injury. This review will focus on the functional 
ties of IC with the complement system and extracellular histones, 
which together with DNA and products of neutrophil granules 
are major components of neutrophil extracellular traps (NETs).
MODeL OF ACUTe LUnG inJURY 
inDUCeD BY igG iMMUne COMPLeXeS
Our focus over the past several years has been related to the 
finding of extracellular histones in the setting of IgGIC-induced 
ALI in mice and the mechanisms related to how the appearance 
of extracellular histones play into the events that result in severe 
compromise of air exchange in the lung (17). The IgGIC–ALI 
model features the intratracheal (i.t.) instillation of rabbit IgG, 
which has high reactivity with bovine serum albumin (BSA). BSA 
is then given intravenously, resulting in IgGIC formation in walls 
of alveoli and interstitial capillaries of lung. This results in a break 
in the vascular–endothelial barrier and the alveolar–epithelial 
barrier, leading to alveolar edema, hemorrhage, and the massive 
influx of polymorphonuclear neutrophils (PMNs) as shown in 
Figure 1 (18, 19). In addition, residential CD11c+F4/80+ alveolar 
macrophages are actively involved during IgGIC–ALI, which 
is similar as in other ALI models (20, 21). Together, activated 
PMNs and macrophages release large amounts of oxidants and 
proteases, resulting in intense damage to the alveolar wall.
iMMUne COMPLeXeS MeDiATe 
COMPLeMenT ACTivATiOn AnD 
APPeARAnCe OF eXTRACeLLULAR 
HiSTOneS
Full expression of the features of injury in the IgGIC model 
of ALI requires participation of the complement system (3). 
The complement system is a conserved arm of innate immune 
defenses. It comprises more than 30 proteins with cascadic pro-
teolytic activation in response to antigen–antibody aggregates 
(classical pathway), foreign surfaces devoid of endogenous com-
plement inhibitors (alternative pathway), or innate  recognition 
of microbial pathogen surfaces (lectin/ficolin pathway). These 
three activation pathways converge on the level of C3/C5 to 
catalyze C5b-9 membrane attack complex formation as a major 
mechanism of IC-mediated tissue injury. In addition, IgG and 
IgM antibody–antigen ICs triggered complement activation 
results in generation of C3a and C5a during ALI. A great deal of 
research work has focused on C5a because it is considered to be 
of higher biological activity as compared to C3a (22). Some time 
ago, we described that i.t. instillation of neutralizing antibodies 
to rat or mouse C5a had protective effects in the setting of IgGIC-
induced ALI (23–25). The surge of C5a in lung homogenates and 
broncho-alveolar lavage fluids (BALFs) was observed about 6 h 
after IC formation (26). Anti-C5a neutralizing antibodies were 
also protective in sepsis-induced ARDS of non-human primates 
(27). C5a ligates with its two receptors, C5aR1 and C5aR2. In 
contrast to initial beliefs, the C5aR2 receptor appears to be 
critically involved in the proinflammatory effects of C5a in lung 
inflammation. In recent studies, use of mice lacking either C5a 
receptor (C5aR1 or C5aR2) markedly reduced development 
of inflammation (19), lung dysfunction and albumin leak into 
alveoli, buildup of PMNs, as well as the appearance in BALF of 
proinflammatory cytokines and chemokines (17).
We earlier described the development of intense inflammation 
and injury in the IgGIC model of ALI in C3-deficient mice (28). 
This had been reported somewhat earlier by another group in 
non-lung IC disease models and the initial conclusion was that 
complement was, therefore, not involved in IC-triggered inflam-
matory events (29). We reproduced and expanded the earlier data 
indicating that full inflammatory damage occurred in C3−/− mice 
after alveolar deposition of IgGIC in mouse lungs. However, we 
also found that our neutralizing antibody to mouse C5a was highly 
protective, suggesting a non-traditional source for generation of 
C5a. We were able to show that specific inhibitors of thrombin 
(such as antithrombin or hirudin) prevented the development of 
IgGIC-induced ALI in C3−/− mice (28). C3a is generated during 
IC-induced inflammation (30), but C3a is less active than C5a 
in lungs (22, 26). Indeed, C3a may act as an anti-inflammatory 
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modulator in direct opposition to C5a (31). In future, studies 
with C3aR-deficient mice in IC-induced ALI could be important 
to obtain a more complete picture. Likewise, the distinctive 
functional roles of C3b and its proteolytically inactive fragment, 
iC3b, remain to be determined in IC-induced ALI. Direct in vitro 
experiments with human thrombin and human C5 demonstrated 
that thrombin was able to generate authentic C5a when incubated 
with C5. The sequence of the peptide that was generated from 
C5 by thrombin was identical to that of C5a generated by the 
complement-derived C5 convertases. This established that C5 
convertases unrelated to complement-generated C5 convertases 
could generate C5a (28). More recent work has demonstrated 
that some activated clotting factors (such as FIXa, FXa, FXIa, and 
plasmin) also have the abilities to generate C3a and C5a when 
incubated with purified human C3 or C5 (32–34). In addition, the 
T-cell expressed protease cathepsin L may provide a mechanism 
of intracellular complement activation by cleavage of endosomal 
and lysosomal C3 into biologically active C3a and C3b (35).
Modern imaging technology including magnetic resonance 
imaging (MRI), together with transmission electron microscopy 
(TEM), has been employed in the model of ALI revealing lung 
consolidation, which correlated to the histological features 
described above (17, 26). Whole-body plethysmography has 
allowed measurements of various parameters of respiratory 
function.
Immune complexes via C5a/C5aR1/C5aR2 promote the 
appearance of extracellular histones, the latter being major 
components of NETs. Extracellular histones, which were found 
in BALF, were quantified by Western blotting and ELISA (17). 
The most convincing evidence that extracellular histones were 
linked to ALI-induced lung dysfunction came from experiments 
in which neutralizing antibodies to histones (H2A and H4), 
which were given i.t. together with recombinant mouse C5a. This 
experimental design led to significant reduction in the intensity of 
ALI in mice (17). The lack of additional neutralizing monoclonal 
antibodies to other histones has prevented more detailed infor-
mation about the roles of individual histones in development of 
ALI. Collectively, these data suggest a pathophysiologic sequence 
of events in which IC deposition promotes complement activa-
tion with release of C5a. Subsequently, C5a via its C5aR1 and 
C5aR2 receptors mediates generation of extracellular histones 
(as a component of NETs) to induce tissue damage. Thereby, 
C5a may link IC deposition with extracellular histones and NETs 
 during inflammatory diseases and ALI/ARDS in particular.
LUnG DAMAGinG eFFeCTS OF 
eXTRACeLLULAR HiSTOneS
Based on the in vivo data incriminating the roles of extracellular 
histones in development of ALI following alveolar deposition of 
IC (see above), we undertook a series of experiments in which 
purified or recombinant histones were instilled intratracheally 
in order to determine their ability to induce ALI as defined by 
morphology, degree of leak of mouse albumin into BALF, as well 
as presence of PMNs and cytokines/chemokines in BALF. For 
most of the studies, a histone mix (obtained from calf thymus) 
consisting of all five histones was first employed, followed by 
use of purified histones. It became immediately apparent that 
extracellular histones in the mixture given intratracheally were 
extremely lung damaging. Morphologically, there was extensive 
alveolar edema, sloughing of alveolar and bronchiolar epithelial 
cells, and alveolar hemorrhage. It was also clear that small venules 
in the lung parenchyma contained numerous thrombi (17).
The airway (i.t.) administration of the histone mix also caused 
significant disturbances in alveolar–capillary gas exchange (17). 
For instance, 15 min after airway delivery of histones, arterial pH 
fell from 7.4 to almost 7.1, indicating severe acidosis. Arterial 
pCO2 rose from 40 to 75  mmHg. Arterial pO2 fell from 88 to 
50 mmHg, representing severe hypoxia. Arterial saturation fell 
from 92 to 48%, all indicating severely compromised gas exchange 
in alveoli (17). Over a period of 6 h, most of these parameters 
returned to the normal or near normal range, suggesting the 
reversibility of these dramatic dysfunctions, the explanation of 
which is not obvious since, on the basis of albumin leak into 
BALF, damage continued until 8  h, after which albumin leak 
began to decrease (17). Extracellular histones caused dramatic 
ventilation changes as indicated by pathological box flow patterns 
of whole-body plethysmography within minutes after purified 
histone i.t. administration (17). Respiratory rates rose from 120 
to 175/min 6 h after histone exposure. Minute ventilation rose 
from 160 to 240  ml/min within the same time period. Similar 
patterns were found for inspiratory flow rates, inspiratory time, 
expiratory time, and total respiratory cycles (17). In contrast 
to the parameters for alveolar–capillary gas exchange which 
returned to normal or near normal 6 h after histone exposure, the 
whole-body plethysmography values remained defective for 24 h.
BALF ReSPOnSeS TO inTRATRACHeAL 
ADMiniSTRATiOn OF PURiFieD 
HiSTOneS
Not surprisingly, airway administration of calf thymus purified, 
mixed histones resulted in the release of numerous cytokines 
and chemokines in BALF, which generally peaked after 8 h (17). 
Proinflammatory peptides in 8h BALF included IL-1β, IL-6, 
Eotaxin, KC, MCP-1, MIP-1α, MIP-1β, RANTES, and TNFα. 
Clearly, a large number of proinflammatory peptides appeared 
after airway instillation of the histone mix, although we do not 
have information on the activities of individual histones. For 
most cytokines and chemokines, levels in BALF were between 
100 and 1000 pg/ml. The presence of diverse proinflammatory 
chemokines and cytokines in the lung is likely related to damag-
ing inflammatory responses triggered by these peptides in various 
amplification loops. What is not known currently are the cellular 
sources of these peptides. These histone-induced chemokines 
most likely promote the influx of PMNs and other white blood 
cells to the alveolar spaces during ALI/ARDS. On the other hand, 
airway instillation of purified histone extracts in C5aR1-deficient 
mice as compared to wild type mice produced similar severities of 
lung injury as evaluated by influx of PMNs and disruption of the 
alveolar/capillary barrier (17). This observation may suggest that 
NETs/extracellular histones do not rely on the liberation of C5a 
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(with subsequent C5aR1 signaling) for mediating tissue damage 
and inflammation.
Taken together, extracellular histones as downstream prod-
ucts of ICs mediate the adverse effects of ALI. It is known that 
extracellular histones are endogenous ligands for TLR2 and TLR4 
receptors (36, 37), which may suggest that these pattern recogni-
tion receptors are involved in mediator production downstream 
of IC-induced inflammation.
eFFeCTS OF PURiFieD HiSTOneS On 
ALveOLAR ePiTHeLiAL CeLL LineS
For these studies, two mouse cell lines, LA-4 and MLE-12, 
were used (17). They are morphologically and phenotypically 
similar to alveolar epithelial cells and contain surfactant. Cells 
were exposed to the histone mix or purified or recombinant H1, 
H3, and H4 (50 μg/ml) for varying periods of time. Histones 
induced significant increases in [Ca2+]i within the first 30 min 
of cell exposure to histones. In the case of MLE-12 cells, cell 
viability was reduced by 60 min of incubation with histones (17). 
Cytotoxicity was confirmed by release of lactate dehydrogenase 
(LDH) in cell culture supernatants, especially in the case of H1, 
H4, and the histone mix. Abundant release of LDH was found 
within the first 60  min. These data suggest that some histones 
can cause cytotoxicity of alveolar epithelial cell lines. The extent 
to which other lung inflammatory cell types, such as PMNs and 
macrophages, exhibit similar responses to histones remains to 
be determined. On the other hand, it is well documented that 
extracellular histones are cytotoxic for endothelial cells during 
in  vitro culture (38–40). It is not determined in IgGIC-ALI to 
what extent there is apoptosis of both epithelial and endothelial 
cells in lung, but it appears likely.
PReSenCe OF eXTRACeLLULAR 
HiSTOneS in BALF FROM HUMAnS  
wiTH ACUTe ReSPiRATORY DiSTReSS 
SYnDROMe
On the basis of animal (rats and mice) studies indicating that 
development of ALI features the appearance of extracellular his-
tones in BALF (17), we have also analyzed BALF from humans with 
ARDS which has many features of animal ALI. ARDS in humans 
is usually characterized by bilateral radiological lung densities 
that are associated with severely compromised air exchange in the 
absence of cardiac etiologies (41, 42). Morphologically, there is 
alveolar hemorrhage, edema, and large alveolar accumulations of 
PMNs. In addition, within alveoli is extensive deposition of “hya-
line membranes” along alveolar surfaces. The deposits represent 
dense buildup of fibrin, which contributes to faulty gas exchange. 
BALFs contain proinflammatory cytokines and chemokines, 
along with the complement activation product, C5a. The major 
risk factors for ARDS are pneumonia, sepsis, acute pancreatitis, 
transfusion reactions, trauma, and many more (42–44). Beyond 
supportive care, there are no FDA-approved drugs for the 
treatment of ARDS. Using cryopreserved BALF samples from 
individuals with normal lung function or individuals with ARDS, 
extracellular histone content was measured both by ELISA and 
by Western blot technology (17). Sequential BALF samples were 
obtained from a few of the ARDS patients. One patient showed 
extracellular histone H4 presence on days 5, 14, and 21, while 
the second patient had strong H4 presence only on day 4 but 
no detectable presence on days 8 and 21. Both H3 and H4 were 
detected in many of the BALF samples. In general, histone pres-
ence in random BALF specimens from ARDS patients was ≥50% 
on days 0–10, falling to around 30% on days 11–16. It is quite 
clear that histone presence may persist for as long as 2  weeks, 
although these data are preliminary and we neither know the full 
composition of histones in BALF nor their degradation kinetics 
or how histone presence relates to the clinical status of patients 
with ARDS.
DiFFeRenCeS BeTween AniMAL 
STUDieS AnD HUMAn iMMUne 
COMPLeX DiSeASeS
Many studies of IC-mediated pathology have relied on animal 
models, e.g., with transgenic mice. These models have been 
invaluable helpful to understand the development and progres-
sion of IC-dependent inflammation and lung injury. On the 
other hand, animal studies have clear limitations when extrapo-
lations are made regarding human diseases. The IgGIC–ALI 
model of rodents is usually non-lethal, and this is in contrast to 
20–40% mortality rates that have been observed in the past for 
humans (42).
It is important to appreciate that mouse and human FcRs 
orthologs do not possess similar effector functions and this is 
further complicated by a misleading nomenclature (13). For 
example, the functional ortholog of mFcγRIV is hFcγRIIIA 
and the functional ortholog of mFcγRIII is hFcγRIIA (45). 
Overall, the species differences in the repertoire of FcRs may also 
alter the natural course of IC disease. More recently, the devel-
opment of humanized mouse models for hFcRs has provided a 
clearer picture. Smith et al. (46) have reported a mouse model 
in which all murine FcγRs were deleted and human FcγRs were 
inserted to the mouse genome. When this humanized FcγRs 
mouse strain was challenged with heat-aggregated human IgG as 
a model of IC-mediated disease, such transgenic mice displayed 
a severe anaphylactic decline in body temperature, which was not 
observed in wild-type control mice (46).
Equipotent cross-reactivity between mouse and human C5a 
and its receptors does exist (47). In addition, transgenic knock-
in mice with a replacement of mouse C5aR1 with the human 
C5aR1 have been described (48) but have not yet been studied 
in IgGIC-ALI.
IgGIC-ALI in rodents may mimic some features of antibody-
dependent transfusion-related acute lung injury (TRALI) 
in humans (49). TRALI develops following transfusion of 
blood products containing antibodies against MHC class I 
and human neutrophil antigen (HNA). This promotes acute 
antibody-dependent recognition of PMNs and endothelial cells 
in lungs. In addition, formation of IC of anti-MHC class I and 
anti-HNA antibodies with their soluble antigens may occur and 
FiGURe 2 | Molecular mechanisms in igGiC-induced ALi. Airway 
position of IgG immune complexes leads to complement activation and 
generation of C5a. C5a interacts with its receptors C5aR1 and C5aR2 on 
neutrophils and on other cell types in lung (alveolar epithelial cells, endothelial 
cells, and macrophages) resulting in a surge of proinflammatory cytokines 
and chemokines. These interactions with neutrophils results in the formation 
of neutrophil extracellular traps (NETs), resulting in the release of extracellular 
histones, which are extremely cell-toxic, proinflammatory, and thrombogenic. 
These responses resolve and there is little evidence of residual functional or 
structural damage.
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trigger PMN activation via FcRs (50). Overall, the contribution 
of IC in human lungs during the natural development of TRALI 
may not be as important as during experimental IgGIC-ALI 
in rodents. On the other hand, the relevance of IC in human 
diseases, such as the cryoglobulinemia syndrome, serum 
sickness-like reactions, vasculitis, membranoproliferative glo-
merulonephritis, and rapidly progressive glomerulonephritis, 
is well established (2).
SUMMARY OF MOLeCULAR evenTS 
in iMMUne COMPLeX-inDUCeD 
ACUTe LUnG inJURY
Figure 2 summarizes our current concepts of molecular events 
responsible for ALI triggered by alveolar deposition of IgGIC. 
Similar events were found with mice in which ALI was induced 
by bacterial lipopolysaccharide (LPS) or recombinant C5a (26).
The IC interact with activating (type I family) FcγRs which are 
present on PMNs, macrophages, B cells, and other immune cells 
(51). FcγRs mediate phagocytosis of IC with subsequent antigen 
processing and major histocompatibility complex-dependent 
presentation of antigens by professional antigen presenting cells 
(51, 52). Activated FcγRs will result in the amplification of the early 
proinflammatory events driving intense lung injury. The effects of 
IC on immune responses largely depend on the type of engaged 
FcγRs (e.g., the activating FcγRI, FcγRIIA, FcγRIIC, FcγRIIIA, 
FcγRIIIB receptors, and the inhibitory receptor FcγRIIB) (52). 
The recognition of IC by individual FcγRs is mainly determined 
by IgG subclasses and Fc-antibody glycosylation (52).
Early events in IgGIC-ALI also trigger complement activa-
tion, presumably via the classical pathway, resulting in genera-
tion of C5a. C5a interacts with its receptors, C5aR1 and C5aR2, 
which exist in large numbers in or on PMNs (53). Much lower 
numbers of binding sites also exist on endothelial cells and 
macrophages. In the case of PMNs activated by C5a, this leads 
to formation of NETs (54). NETs contain extracellular strands 
of DNA and various proinflammatory proteins (myeloper-
oxidase, proteases, and histones) that have substantial injurious 
effects on a variety of cells in the lung (55). In the meantime, 
large numbers of proinflammatory peptides appear in BALF 
(described above). These mediators cause lung phagocytes to 
release oxidants and proteases that damage a variety of resident 
cells in lung. Rather surprisingly, the IgGIC model in rodents 
progresses to “resolution” (disappearance of inflammatory cells 
and mediators), resulting in return of the lung to normal mor-
phology and function. This is in contrast to ARDS in humans, 
where mortality rates are at least around 20% despite critical 
care, supportive treatments. ARDS in humans may lead to 
fibrosis alveolitis (56). Very little is known about how the lung 
can sustain severe inflammatory injury without experiencing 
evidence of permanent structural and functional derangements. 
It is possible that mesenchymal or hematopoietic stem cells 
might be responsible for recovery (57).
COnCLUSiOn
It is clear that following alveolar deposition of IgGIC, C5a, or 
LPS, ALI develops in a manner that is C5a-dependent and C5a 
receptor-dependent. In these models, PMN activation occurs, 
resulting in NET formation and resultant release of extracel-
lular histones together with PMN products, such as proteases, 
myeloperoxidase, and oxidants, that are lung damaging. The 
preliminary data in patients with ARDS confirms the presence of 
extracellular histones in BALF. The experimental evidence sug-
gests that extracellular histones are highly proinflammatory and 
thrombogenic in the lung. A constraint in full understanding of 
such events is the current lack of quantitative ELISA technology 
that will reliably measure amounts of individual histones and 
NET-predisposing histone modifications. Versions of mass spec-
tometry can identify the presence of individual histones using 
laborious technology, but in such situations, mass spectrometry 
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is largely non-quantitative. It is imperative that reliable ELISA 
technology be developed.
In addition, we still know very little about the molecular 
pathways of post translational modifications of histones, such as 
conversion of arginine residues in histones to citrullination prod-
ucts. It is known that such changes, caused by peptidyl arginine 
deiminase 4 (PAD4), converts arginine residues to citrullinated 
residues which may confer autoimmune epitopes on histones, 
resulting in autoantibodies which may exacerbate autoimmune 
diseases, such as small-vessel vasculitis and SLE (58, 59). Very 
little is known about how such post-transitional modifications 
of histones may affect biological activities of histones. In addi-
tion, the precise intracellular pathways by which IC trigger NET 
formation and histone release remain to be determined, but 
most likely involve FcγRs. IC may contain nucleic acids from 
dead cells (such nucleic acids are also a major component of 
NETs) for modulation of type I interferon-dependent immune 
responses (60). Accordingly, much work needs to be done to bet-
ter  understand the pathobiology of histones and to connect all the 
dots that link extracellular histones and NETs with IC-mediated 
tissue damage.
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